U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07038447) titled 'A Study of KITE-363 in Participants With Refractory Autoimmune Diseases' on June 18.
Brief Summary: This study will have two Phases: Phase 1a and Phase 1b. The goal of this clinical study is to learn more about the study drug KITE-363, to establish dosing, tolerability, safety, and preliminary efficacy of KITE-363 in participants with refractory autoimmune diseases.
The primary objectives of this study are:
Phase 1a: To evaluate the safety and tolerability of KITE-363 in participants with autoimmune disease. To determine the recommended dose for Phase 1b.
Phase 1b: To evaluate the safety and efficacy of KITE-363 in participants w...